A carregar...

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma

The combination of targeted therapy with BRAF and MEK inhibitors has become the standard of care in patients with BRAF(V600E) mutant melanoma, but responses are not durable. In addition, the impressive clinical benefits with anti-PD-1 and anti-PD-L1 antibodies (Ab) in patients with heavily pretreate...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoimmunology
Main Authors: Homet Moreno, Blanca, Mok, Stephen, Comin-Anduix, Begonya, Hu-Lieskovan, Siwen, Ribas, Antoni
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2015
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5006894/
https://ncbi.nlm.nih.gov/pubmed/27622011
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1052212
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!